Suicide gene stem cells take aim at glioblastoma
NCT ID NCT07143812
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called MSC11FCD for people with newly diagnosed glioblastoma, an aggressive brain cancer. The treatment uses donor stem cells that carry a 'suicide gene' and are injected into the brain during surgery to kill any remaining cancer cells. The study will enroll 10 patients to check if the treatment is safe and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MSC11FCD (stem cells with a suicide gene)
What this could lead to
If it works, this could point toward a new way to kill leftover tumor cells after surgery and delay glioblastoma recurrence.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. The approach may not work in humans, and there are risks from the surgery and the stem cells themselves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bundang CHA Medical Center
RECRUITINGSeongnam, Kyunggido, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••